Canopy Growth's Losses Are Shrinking Fast. The Market Still Thinks the Company Is Going to Zero.

The old story is baked into the tape: Canopy Growth is a cash-burning cannabis operator heading nowhere. The stock has lost 35% over the past year and trades at $0.93, a fraction of where it was two years ago. AInvest's aggregate consensus is Hold, and the fundamental rating sits at 2.01 out of 10 — a score that reflects the same narrative that has dragged this stock down for years.

The numbers from the first quarter of fiscal 2027 say something different. The net loss narrowed 68% to $14.6 million from $44.9 million a year earlier. Revenue grew 13% to $81.2 million, with every segment contributing. Adjusted gross margin — which strips out the one-time inventory step-up charges from the MTL Cannabis acquisition — jumped from 25% to 31%. The adjusted EBITDA loss (earnings before interest, taxes, depreciation, and amortization, a rough proxy for operating cash generation) halved to $3.2 million from $7.9 million.

EPS of -$0.03 beat the consensus estimate of -$0.04 by half. That is not a headline you expect from a company that still prints losses.

The market has not responded. CGC closed at $0.93 the day before the print, down 18% year-to-date and down 9.5% over the past four months. The crowd is still pricing the company that reported a $262.9 million annual loss a year ago.

The one metric that matters

Free cash flow is the hard proof. On a trailing twelve-month basis, Canopy's free cash flow burn was $59.4 million, which is 35% better than the prior year. That improvement came from lower debt, lower interest costs, tighter operating expenses, and the capital structure fix the company completed in January 2026 that flipped its net position from $172 million of net debt to $131 million of net cash. The balance sheet today shows $261 million in cash against $302 million in total debt — a net debt position of $94 million that is manageable for a company this size.

The quarterly snapshot is less clean. First-quarter free cash flow was a $25.7 million outflow, worse than the $11.6 million burn in the prior-year quarter. Management attributed the difference to working capital timing — cash tied up in inventory and receivables rather than spent on operations. That is a legitimate explanation for a single quarter but not a pattern you want to see repeat. If working capital remains a headwind through the MTL integration, the path to positive free cash flow stretches.

Still, the direction of travel on the trailing number is the right one. The burn rate was $176.6 million in fiscal 2025. It came down to $69.1 million in fiscal 2026. The trailing twelve months are at $59.4 million. That is a consistent decline.

What management is banking on

Management has a stated target: positive adjusted EBITDA during fiscal 2027, with the second half of the year carrying the weight. That is not vague wishful thinking. The adjusted EBITDA loss has shrunk every quarter since late 2024: from the deep losses of fiscal 2025 to a $20.2 million annual loss in fiscal 2026, to a $3.2 million quarterly loss in Q1 FY2027. The quarter-over-quarter trend is the proof path.

Three things are supposed to drive the remainder of the improvement. The MTL Cannabis acquisition, completed in fiscal 2026, added premium flower supply and pushed Canopy into the top two in Canada for premium flower, infused pre-rolls, and oils and softgels. That product quality advantage should feed into the medical channel, which grew 22% this quarter as insured customer numbers expanded. And cost discipline is real — the company has captured $21 million in annualized SG&A savings, even though absolute SG&A was 6% higher this quarter due to MTL integration costs.

On the hardware side, Storz & Bickel — Canopy's premium vaporizer brand — grew revenue 6% and saw gross margin explode from 29% to 48%. That margin expansion came from cost rationalization and the recovery of U.S. tariffs that had weighed on the business earlier. A 48% margin on a $16 million revenue stream is not the growth engine, but it is a cash contribution that does not require the same operating intensity as the cannabis business.

The counterargument

Here is what keeps the skeptics awake: Canopy is still losing money. The TTM operating margin is -57%. Return on invested capital is -19%. The adjusted EBITDA loss for the quarter was only $3.2 million — which sounds close to zero until you remember that capital expenditures, debt interest, and working capital swings still eat through cash. The $25.7 million quarterly free cash flow outflow is the number that makes you pause.

And the Canadian cannabis market itself has been unforgiving. Revenue growth of 13% is good relative to Canopy's own trajectory, but it is not the kind of top-line acceleration that overwhelms structural risk. Adult-use grew 10%, which is fine but not explosive. International markets — which still represent a small $9.6 million slice — grew 10%, led by Poland.

The market is not wrong to demand more proof before it changes its mind. What the market may be wrong about is the pace at which that proof is arriving.

The bridge

Management expects positive adjusted EBITDA in fiscal 2027. If the adjusted EBITDA loss continues shrinking at roughly the same pace — a $4.7 million improvement in one quarter — the company needs only two more quarters of similar progress to cross the line. Even if the improvement slows, a low-single-digit-million adjusted EBITDA profit for the full year would be a structural change for a business that lost $20.2 million on that same measure last year.

The financial bridge works like this: revenue growing in the low-to-mid teens, adjusted gross margin holding above 30%, operating expenses flat or declining, and adjusted EBITDA crossing into positive territory. That is the scenario where the $300 million enterprise value — the current market cap minus net cash — starts looking like a floor rather than a ceiling.

Simple multiples, not DCF models, tell the story here. At $300 million in enterprise value, Canopy trades at 1.47 times trailing sales. If the company produces $10 million in annual adjusted EBITDA and the market assigns it a 25 times multiple — a generous but not absurd number for a company crossing the profitability threshold — the implied enterprise value is $250 million. That is below today's $300 million. So the current price already reflects a significant degree of turnaround belief.

For the stock to move meaningfully higher, the adjusted EBITDA number has to exceed what today's enterprise value implies. That means mid-teens million in annual adjusted EBITDA, or a multiple expansion that the market has not yet signaled.

What would prove this wrong

The tripwire is clear: if the next two quarters show adjusted EBITDA losses widening rather than narrowing, the profitability thesis breaks. A second consecutive quarter with free cash flow outflows above $25 million would also undermine the cash-convergence narrative. And if MTL integration drags longer than expected — adding costs without delivering the margin and volume gains management is counting on — the entire bridge slows.

Equally important: if Canada's cannabis market fails to grow or if regulatory headwinds (such as the Veterans Affairs reimbursement reduction that already hit this quarter) compound, the top-line engine stalls and margin expansion becomes academic.

The setup

Canopy is not a company I would buy with conviction today. The free cash flow bridge has not arrived, and the adjusted EBITDA target is still guidance, not a demonstrated run rate. But it is a company where the market narrative has fully reset to the worst case — and the operating numbers are moving in the opposite direction. Losses down 68%. Margins up 600 basis points. Revenue growing from all segments. Burn rate on a multi-quarter improving trajectory.

The stock at $0.93 is priced for continued deterioration. If the adjusted EBITDA path holds, the market will have to reckon with the fact that it may have been too early to give up. If it doesn't, there is not much left to sell.

The thing to watch is the next earnings print in November. One quarter of further adjusted EBITDA improvement and this setup gets cleaner. A reversal, and the old story is still alive.

Discipline over ego: the proof point is adjusted EBITDA trending to zero, then positive. Until it does, the position is a watch, not a conviction. When the financial bridge clears, the entry gets easier.